Vera Therapeutics - VERA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.29
  • Forecasted Upside: -30.61%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$46.53
▼ -1.44 (-3.00%)

This chart shows the closing price for VERA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERA

Analyst Price Target is $32.29
▼ -30.61% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $32.29, with a high forecast of $56.00 and a low forecast of $22.00. The average price target represents a -30.61% upside from the last price of $46.53.

This chart shows the closing price for VERA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Vera Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2022
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/17/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/16/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024GuggenheimReiterated RatingBuy ➝ Buy$56.00Low
3/27/2024GuggenheimBoost TargetBuy ➝ Buy$27.00 ➝ $56.00Low
3/21/2024WedbushBoost TargetNeutral ➝ Neutral$21.00 ➝ $34.00Low
1/26/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$29.00 ➝ $37.00Low
1/26/2024WedbushBoost TargetNeutral ➝ Neutral$16.00 ➝ $21.00Low
1/25/2024OppenheimerInitiated CoverageOutperform$26.00Low
1/8/2024Cantor FitzgeraldInitiated CoverageOverweightLow
12/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
12/18/2023Raymond JamesInitiated CoverageOutperform$29.00Low
11/30/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$25.00 ➝ $22.00Low
11/10/2023Jefferies Financial GroupUpgradeHold ➝ Buy$18.00 ➝ $26.00Low
9/26/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $25.00Low
8/15/2023GuggenheimInitiated CoverageBuy$27.00Low
8/11/2023WedbushBoost TargetNeutral ➝ Neutral$12.00 ➝ $16.00Low
5/12/2023WedbushBoost Target$6.00 ➝ $9.00Low
5/12/2023HC WainwrightLower Target$11.00 ➝ $10.00Low
4/12/2023JPMorgan Chase & Co.Lower TargetOverweight$38.00 ➝ $22.00Low
3/29/2023HC WainwrightLower TargetBuy$15.00 ➝ $11.00Low
1/4/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $6.00Low
1/4/2023WedbushDowngradeOutperform ➝ Neutral$33.00 ➝ $8.00Low
1/4/2023HC WainwrightLower TargetBuy$36.00 ➝ $15.00Low
11/18/2022JPMorgan Chase & Co.Boost TargetOverweight$35.00 ➝ $38.00Low
8/22/2022HC WainwrightBoost TargetBuy$35.00 ➝ $36.00Low
7/12/2022JPMorgan Chase & Co.Initiated CoverageOverweight$35.00N/A
5/2/2022HC WainwrightInitiated CoverageBuy$35.00Low
4/18/2022WedbushInitiated CoverageOutperform$32.00Medium
3/28/2022Lifesci CapitalReiterated RatingOutperformLow
6/8/2021Evercore ISIInitiated CoverageOutperform$24.00High
6/8/2021Jefferies Financial GroupInitiated CoverageBuyHigh
6/8/2021CowenInitiated CoverageOutperformHigh
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/19/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/18/2023
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 8 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/17/2024
  • 15 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/16/2024

Current Sentiment

  • 15 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Vera Therapeutics logo
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $46.53
Low: $45.75
High: $47.88

50 Day Range

MA: $43.58
Low: $37.41
High: $49.14

52 Week Range

Now: $46.53
Low: $6.07
High: $50.78

Volume

1,124,222 shs

Average Volume

1,314,675 shs

Market Capitalization

$2.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Vera Therapeutics?

The following Wall Street analysts have issued stock ratings on Vera Therapeutics in the last twelve months: Cantor Fitzgerald, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Oppenheimer Holdings Inc., Raymond James, and Wedbush.
View the latest analyst ratings for VERA.

What is the current price target for Vera Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Vera Therapeutics in the last year. Their average twelve-month price target is $32.29, suggesting a possible downside of 30.6%. Guggenheim has the highest price target set, predicting VERA will reach $56.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $22.00 for Vera Therapeutics in the next year.
View the latest price targets for VERA.

What is the current consensus analyst rating for Vera Therapeutics?

Vera Therapeutics currently has 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERA will outperform the market and that investors should add to their positions of Vera Therapeutics.
View the latest ratings for VERA.

What other companies compete with Vera Therapeutics?

How do I contact Vera Therapeutics' investor relations team?

The company's listed phone number is 650-770-0077 and its investor relations email address is [email protected]. The official website for Vera Therapeutics is veratx.com. Learn More about contacing Vera Therapeutics investor relations.